The Company's proprietary triple combination includes a novel cystic fibrosis transmembrane conductance regulator (CFTR) amplifier, third generation corrector and potentiator, known as PTI-428, PTI-801 and PTI-808, respectively. The
The acquisition is the culmination of a June 2014 alliance between Inception and Roche to discover and develop novel small molecules that promote remyelination of nerve fibers damaged
Advanced CCSC is the deadliest non-melanoma skin cancer. Cemiplimab is an investigational human monoclonal antibody targeting the checkpoint inhibitor PD-1 (programmed cell death protein-1). The MAA for cemiplimab
Pfizer views this agreement as an attractive opportunity to support the continued development of allogeneic CAR T therapy in a highly focused and skilled manner. Pfizer will continue
MAVERICK-HCM is the first clinical trial of mavacamten in non-obstructive HCM, expanding its potential use to an additional sub-type of HCM beyond the obstructed form of the disease.
A pre-specified interim analysis, conducted by an independent Data Safety Monitoring Board (DSMB) of the efficacy and safety data for the study in an overall population of 275
The preliminary safety data showed that tafamidis was generally well tolerated in this population and no new safety signals were identified. The ATTR-ACT study was designed to assess
The approval is for patients whose minimal residual disease (MRD) is greater than or equal to 0.1 percent. This indication is approved under accelerated approval based on MRD
Under this collaboration, Actinium will utilize its AWE Platform to conjugate and label selected Astellas targeting agents with the powerful actinium-225 (225Ac) payload. Actinium will also be responsible
bluebird bio corporate development and strategy oncology franchise leader and senior vice president Joanne Smith-Farrell said: "Entering into this co-development and co-promotion partnership with Celgene is a significant
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.